Table 2.
Number Needed to Treat and Costs per Hospitalization Prevented
| Number Needed to Treat | Cost per Hospitalization Prevented | ||||||
|---|---|---|---|---|---|---|---|
| Drug | Cost/Patient | 2.5% Risk | 5% Risk | 10% Risk | 2.5% Risk | 5% Risk | 10% Risk |
| Fluvoxamine (meta-analysis) | 14 | 160 (96–1334) | 80 (48–667) | 40 (24–334) | 2244 (1346–18 709) | 1122 (673–9355) | 561 (337–4684) |
| Colchicine (meta-analysis) | 37 | 182 (103–40 000) | 91 (52–20 000) | 46 (26–10 000) | 6667 (3773–1 465 200) | 3333 (1905–732 600) | 1685 (952–366 300) |
| Inhaled corticosteroids (meta-analysis)a | 132 | 143 (89–800) | 72 (45–400) | 36 (23–200) | 18 819 (11 712–105 280) | 9475 (5922–52 640) | 4738 (3027–26 320) |
| Nirmatrelvir/ritonavir (meta-analysis)b | 530 | 48 (44–57) | 24 (22–29) | 12 (11–15) | 25 440 (23 320–30 210) | 12 720 (11 660–15 370) | 6360 (5830–7950) |
| Molnupiravir (meta-analysis)a | 700 | 100 (72–236) | 50 (36–118) | 25 (18–59) | 70 000 (50 400–165 200) | 35 000 (25 200–82 600) | 17 500 (12 600–41 300) |
| Remdesivir (phase 3) | 1872 | 56 (45–160) | 28 (23–80) | 14 (12–40) | 104 832 (84 240–299 520) | 52 416 (43 056–149 760) | 26 208 (22 464–74 880) |
| Sotrovimab (phase 3) | 2100 | 50 (44–77) | 25 (22–39) | 13 (11–20) | 105 000 (92 400–161 700) | 52 500 (46 200–81 900) | 27 300 (23 100–42 000) |
| Casirivimab/imdevimab (phase 3) | 2100 | 57 (50–73) | 29 (25–37) | 15 (13–19) | 119 700 (105 000–153 300) | 60 900 (52 500–77 700) | 31 500 (27 300–39 900) |
| Bamlanivimab/etesevimab (phase 3)b | 2100 | 58 (48–99) | 29 (24–50) | 15 (12–25) | 121 800 (100 800–207 900) | 60 900 (50 400–105 000) | 31 500 (25 200–52 500) |
Lowest drug prices for repurposed therapy (eg, GoodRx) may underestimate the costs of acquisition for patients/drug plans. Monoclonal antibody and remdesivir prices do not include price of administration. Shaded monoclonal antibodies likely have significantly reduced efficacy against the Omicron variant.
Abbreviation: COVID-19, coronavirus disease 2019.
Fixed-effects models had moderate heterogeneity.
All-cause hospitalization not provided; COVID-19-related hospitalizations used, which may inflate efficacy.